UNSPSC 51142536: Piribedil

This classification denotes a dopamine agonist with the molecular formula C16H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DO22K1PRDJ, chemically known as 2-(4-(3,4-methylenedioxybenzyl)piperazino)pyrimidine but generally known as piribedil, which bears US NIH Compound Identifier 4850. European Medicines Agency schedules Piribedil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09908MIG.

UNSPSC 51142536 Piribedil is a Commodity code that captures pharmaceutical procurement by state and local agencies, though recent opportunities tagged under this code show minimal direct activity aligned with piribedil itself. The actual buying under this code spans a broader pharmaceutical landscape: state and local health departments, cooperative purchasing alliances, and county health systems are procuring naloxone and drug deactivation systems for harm-reduction programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing frameworks, and exploring direct-to-manufacturer prescription fulfillment models to reduce costs and improve access. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The work spans supply of finished pharmaceutical units for community health initiatives, establishment of master-service agreements for pharmaceutical distribution through authorized wholesalers, and information-gathering for emerging direct-contracting models outside traditional pharmacy benefit manager channels.

Recent activity concentrates in the South and upper Midwest. Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to support community health. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract term beginning July 1, 2026, and awards based 75 percent on price competitiveness. The Texas HHS Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling early-stage exploration of non-traditional pharmaceutical supply models. All three opportunities require federal compliance standards (FDA requirements, Drug Supply Chain Security Act adherence, cGMP certification), EDI capability, and established insurance coverage; the MMCAP cooperative includes performance penalties ranging from $200 to $1,500 per violation for reporting or onboarding failures.